Generic Name
Repaglinide
FDA approval date: November 22, 2013
Classification: Glinide
Form: Tablet
What is Repaglinide?
Repaglinide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitation of Use: Repaglinide tablets should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. Repaglinide is a glinide indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus . Limitation of Use: Not for treatment of type 1 diabetes mellitus or diabetic ketoacidosis .
Approved To Treat
Top Global Experts
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
A Phase 1, Open Label, Drug Interaction Study to Evaluate the Effect of ZYN002 on the Pharmacokinetics of CYP3A4, CYP2C19, CYP2C9, CYP2D6, CYP1A2, CYP2C8, and CYP2B6 Probe Substrates, and Valproate in Healthy Adult Participants
Summary: This study is an open-label drug-drug interaction (DDI) study of ZYN002 transdermal gel and multiple drugs.
Study of the Pharmacokinetic Effect of Y-3 for Injection on Repaglinide Tablets, Warfarin Sodium Tablets, and Omeprazole Enteric-Coated Capsules in Healthy Participants
Summary: The primary goal of this clinical trial is to evaluate the effect of Y-3 for injection on the pharmacokinetic profile of the sensitive finger substrates repaglinide tablets, warfarin sodium tablets, and omeprazole enteric-coated capsules for CYP2C8, CYP2C9, and CYP2C19 in Chinese healthy participants, to evaluate whether Y-3 for injection(40mg) will have clinical drug interactions with repaglinide...